Introduction First-generation therapeutics have improved clinical outcomes in patients
infected with SARS-CoV-2. However, viral evolution has produced variants and subvariants …

Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a public health concern …

Objectives Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become
established in the human population, making the need to develop safe and effective …

This multicenter, double-blind, phase 2a part of a phase 2/3 study assessed the efficacy and
safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Background: Limited treatment options exist for patients with mild-to-moderate coronavirus
disease 2019 (COVID-19), irrespective of vaccination history or risk status. Ensitrelvir is a …

Introduction The COVID-19 pandemic stimulated the development of several therapeutic
tools with several degrees of success. Ensitrelvir, a protease inhibitor that blocks the …

Ensitrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro or
Nsp5), is clinically useful against SARS-CoV-2 including its omicron variants. Since most …

Antivirals with proven effectiveness against the Omicron SARS-CoV-2 variant are required
for COVID-19 treatment in hospitalized patients, particularly those with severe underlying …

Lately, nitrogenous heterocyclic antivirals, such as nucleoside-like compounds, oxadiazoles,
thiadiazoles, triazoles, quinolines, and isoquinolines, topped the therapeutic scene as …

The persistent pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants accentuates the great …